Defense Secretary Pete Hegseth has announced a new initiative to test U.S. service members' testosterone levels annually and offer hormone replacement therapy to those diagnosed with low testosterone, framing the effort as part of building what he called a "High-T Department of War."

In a July 15 post on X, Hegseth said "war fighters age 30 and older" would be screened as part of their existing annual health assessments. Service members under age 30 could voluntarily opt in to testing. A Pentagon spokesperson confirmed the screening would be mandatory for all active duty and reserve personnel 30 and older.

Hegseth described the initiative in a video, saying it was "not about artificial enhancement" but rather about "restoring and optimizing your natural capabilities, protecting your longevity and ensuring you have the biological foundation required to sustain the fight."

What the Left Is Saying

Progressive critics have raised concerns about the policy's medical necessity and potential implications for service members' autonomy over their own bodies. Some Democratic lawmakers and advocacy groups argue that mandating hormone testing raises ethical questions about military personnel being subject to additional medical interventions without clear justification.

Representative Seth Moulton, a Massachusetts Democrat and Marine Corps veteran, has questioned whether this initiative represents the best use of defense resources amid ongoing challenges with recruitment and retention. "We should be focused on concrete readiness improvements, not wellness fads," Moulton said in a statement.

Organizations including the Service Women's Action Network have noted that the policy could disproportionately affect female service members, for whom testosterone testing standards are less established. There is no FDA-approved testosterone replacement treatment specifically for women, although off-label prescriptions can be provided with dose adjustments.

Medical experts quoted by PolitiFact emphasized that testosterone levels fluctuate significantly and that a single low reading does not warrant intervention. "For people with borderline-low testosterone levels, a repeat test would show a normal range about 30% of the time," Harvard Health reported.

Civil liberties advocates have also flagged privacy concerns, questioning how medical data from widespread hormone screening might be stored, used, or potentially shared within the defense bureaucracy.

What the Right Is Saying

Conservative supporters argue that optimizing troop physical readiness represents a legitimate national security priority. Republican lawmakers have largely embraced Hegseth's framing, noting that maintaining peak physical condition has always been part of military service expectations.

Senator Roger Wicker, Republican of Mississippi and chair of the Senate Armed Services Committee, called the initiative "a commonsense approach to ensuring our warfighters are operating at full capacity." He added that similar health optimization programs exist in allied militaries.

Defense hawks have pointed to recruiting challenges facing all branches as justification for maximizing the capabilities of current personnel. With the military missing recruitment targets in recent years, some argue that keeping experienced service members healthier and on active duty longer serves strategic interests.

Proponents note that testosterone replacement therapy would remain voluntary for those who test positive for low levels. The policy does not mandate treatment, only screening, they emphasize. Conservative commentators have echoed Hegseth's characterization of the initiative as "restoring" natural hormone levels rather than artificial enhancement.

What the Numbers Show

According to the Endocrine Society, normal testosterone levels for adult men span from about 300 to 1,000 nanograms per deciliter. A 2017 study of more than 9,000 men in the U.S. and Europe found similar ranges between 264 and 916 nanograms per deciliter.

For women, testosterone levels are naturally much lower, generally ranging from 15 to 46 nanograms per deciliter according to Cleveland Clinic data.

Testosterone levels begin declining in men at roughly age 30, dropping by about 1% to 2% per year. The benchmark for diagnosing low testosterone typically requires a man's level to repeatedly fall below 280 to 320 nanograms per deciliter, accompanied by symptoms such as lowered sex drive, fatigue, and lost muscle mass.

The therapy carries documented risks. According to medical sources, external testosterone use can lead to decreased sperm production, testicle shrinkage, worsened sleep apnea, increased red blood cell production raising clotting risks, prostate growth, and breast tenderness or enlargement in men. For women, side effects can include acne, excessive sweating, and increased facial or body hair growth.

The Defense Department has not released cost estimates for implementing the screening program across all branches.

The Bottom Line

The testosterone testing initiative represents one of Hegseth's most visible policy moves since taking office, reflecting his stated priority on physical readiness. The program remains in early implementation stages with many operational details still undefined.

Key questions remain unanswered: How will the military handle false positives from fluctuating hormone levels? What accommodations will be made for service members whose religious or personal beliefs oppose hormone therapy? Will female service members face different standards given the lack of established benchmarks for women?

The policy's success will likely depend on how these implementation challenges are resolved. Critics within the medical community note that testosterone optimization is not straightforward, with significant disagreement about treatment thresholds and long-term effects. Supporters argue that providing options to service members experiencing legitimate hormone deficiencies serves their wellbeing and military effectiveness alike.

What to watch: The Pentagon has yet to release detailed implementation guidelines, screening protocols, or cost projections. Congressional oversight hearings on the initiative are expected as more details emerge.